IL299512A - Pyridine-1,5-diones exhibitng mnk inhibition and their method of use - Google Patents

Pyridine-1,5-diones exhibitng mnk inhibition and their method of use

Info

Publication number
IL299512A
IL299512A IL299512A IL29951222A IL299512A IL 299512 A IL299512 A IL 299512A IL 299512 A IL299512 A IL 299512A IL 29951222 A IL29951222 A IL 29951222A IL 299512 A IL299512 A IL 299512A
Authority
IL
Israel
Prior art keywords
compound
alkyl
cycloalkyl
heterocyclyl
group
Prior art date
Application number
IL299512A
Other languages
English (en)
Hebrew (he)
Original Assignee
4E Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4E Therapeutics Inc filed Critical 4E Therapeutics Inc
Publication of IL299512A publication Critical patent/IL299512A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL299512A 2020-06-30 2021-06-30 Pyridine-1,5-diones exhibitng mnk inhibition and their method of use IL299512A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063046325P 2020-06-30 2020-06-30
PCT/US2021/039982 WO2022006331A2 (en) 2020-06-30 2021-06-30 Pyridine-1,5-diones exhibitng mnk inhibition and their method of use

Publications (1)

Publication Number Publication Date
IL299512A true IL299512A (en) 2023-02-01

Family

ID=79315594

Family Applications (1)

Application Number Title Priority Date Filing Date
IL299512A IL299512A (en) 2020-06-30 2021-06-30 Pyridine-1,5-diones exhibitng mnk inhibition and their method of use

Country Status (11)

Country Link
US (1) US20230286983A1 (cg-RX-API-DMAC7.html)
EP (1) EP4171565A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023533616A (cg-RX-API-DMAC7.html)
KR (1) KR20230041715A (cg-RX-API-DMAC7.html)
CN (1) CN116194112A (cg-RX-API-DMAC7.html)
AU (1) AU2021300363A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022026275A2 (cg-RX-API-DMAC7.html)
CA (1) CA3183551A1 (cg-RX-API-DMAC7.html)
IL (1) IL299512A (cg-RX-API-DMAC7.html)
MX (1) MX2022016516A (cg-RX-API-DMAC7.html)
WO (1) WO2022006331A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4363419A4 (en) * 2021-06-30 2025-06-11 4E Therapeutics, Inc. Spirocyclic pyridine-1,5-diones exhibiting mnk inhibition and their method of use
EP4646266A1 (en) * 2023-01-04 2025-11-12 4E Therapeutics, Inc. Solid state forms of mnk inhibitors
WO2026006417A1 (en) * 2024-06-26 2026-01-02 4E Therapeutics, Inc. Formulations of mnk inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012009735A (es) * 2010-02-26 2012-09-12 Boehringer Ingelheim Int 4-[cicloalquiloxi (hetero) arilamino] tieno [2,3-d] pirimidinas que tienen actividad inhibitoria de mnk1/mnk2 para composiciones farmaceuticas.
RU2014111055A (ru) * 2011-08-22 2015-09-27 Мерк Шарп И Доум Корп. 2-спирозамещенные иминотиазины и их моно- и диоксиды в качестве ингибиторов bace, композиции и их применение
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 MnK抑制劑及其相關方法
JP2018531266A (ja) * 2015-10-22 2018-10-25 セルビタ エス.エー. ピリドン誘導体およびキナーゼ阻害剤としてのその使用
CA3002558A1 (en) * 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
GB201520500D0 (en) * 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
JP2019510061A (ja) * 2016-03-31 2019-04-11 サウス オーストラリアン ヘルス アンド メディカル リサーチ インスティテュート リミテッドSouth Australian Health And Medical Research Institute Limited 高脂肪食関連疾患を阻害する方法
CA3064000A1 (en) * 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
EP3870178A4 (en) * 2018-10-24 2022-08-03 Effector Therapeutics Inc. Crystalline forms of mnk inhibitors
CN111484494B (zh) * 2019-01-29 2022-09-13 诺沃斯达药业(上海)有限公司 抑制mnk1和mnk2的多环化合物
EP3972593B1 (en) * 2019-05-23 2025-07-02 Board of Regents, The University of Texas System Inhibitor of mnk for the treatment of neuropathic pain
CN110256432A (zh) * 2019-06-27 2019-09-20 诺沃斯达药业有限公司 抑制mnk1和mnk2的多环化合物

Also Published As

Publication number Publication date
CA3183551A1 (en) 2022-01-06
WO2022006331A9 (en) 2022-03-03
KR20230041715A (ko) 2023-03-24
MX2022016516A (es) 2023-03-28
WO2022006331A3 (en) 2022-02-10
JP2023533616A (ja) 2023-08-03
WO2022006331A8 (en) 2023-03-16
EP4171565A4 (en) 2024-11-27
US20230286983A1 (en) 2023-09-14
EP4171565A2 (en) 2023-05-03
CN116194112A (zh) 2023-05-30
WO2022006331A2 (en) 2022-01-06
BR112022026275A2 (pt) 2023-03-14
AU2021300363A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
ES2986581T3 (es) Antagonistas del receptor muscarínico de acetilcolina M4
US20180065917A1 (en) Immune checkpoint inhibitors, compositions and methods thereof
CN111556747A (zh) 用于调节肌肉功能的dux4诱导的抑制剂
PT2139892E (pt) Pirimidodiazepinas substituídas úteis como inibidores da plk1
WO2023283373A1 (en) 3,4-methylenedioxymethamphetamine and related psychedlics and uses thereof
BR112014023460B1 (pt) Composto, formulação farmacêutica, uso de um composto
WO2014151729A1 (en) Compounds and compositions for the treatment of parasitic diseases
EP4380566A1 (en) Methods of treating migraine with mnk inhibitors
US20250049748A1 (en) Analogs of 4-bromo-2,5-dimethoxyphenethylamine
US11858938B2 (en) Imidazo-fused heterocycles and uses thereof
WO2022006331A9 (en) Pyridine-1,5-diones exhibitng mnk inhibition and their method of use
WO2018067685A1 (en) Small molecule ampk activators
PT1727817E (pt) Derivados de azabiciclooctan-3-ona e seu uso
AU2018205277A1 (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases
TW202517271A (zh) Nek7激酶抑制劑之醫藥組合物
EP4719413A1 (en) Inhibitors of canine janus kinase and uses thereof
WO2022226182A1 (en) Nek7 inhibitors
KR20230170684A (ko) Lrrk2 키나제 억제제로서 유용한 피리미딘 유도체
LU102907B1 (en) Citrate transporter modulators and uses thereof
US20240002395A1 (en) Compounds and their use for treating neuropathic pain
CN117185987A (zh) 脒类和胍类衍生物、其制备方法及其在医药上的应用
CN122003417A (zh) 一种nek7抑制剂、药物组合物及其用途
CN103319456B (zh) 二氢吡啶类化合物、其组合物、制备方法和用途
CN119968357A (zh) 酰胺前药及其用途
KR20150051016A (ko) 구아니딘 화합물 및 이의 용도